Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 23.35 -0.21% -0.05
ACOR closed down 0.21 percent on Friday, April 20, 2018, on 39 percent of normal volume.

Earnings due: Apr 26

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ACOR trend table...

Date Alert Name Type % Chg
Apr 20 Lizard Bullish Bullish Day Trade Setup 0.00%
Apr 20 Bollinger Band Squeeze Range Contraction 0.00%
Apr 20 Doji - Bullish? Reversal 0.00%
Apr 19 Downside 200 DMA Break Bearish -0.21%
Apr 19 Bollinger Band Squeeze Range Contraction -0.21%
Apr 19 Stochastic Reached Overbought Strength -0.21%
Apr 19 Overbought Stochastic Strength -0.21%
Apr 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.30%
Apr 18 200 DMA Support Bullish -2.30%
Apr 18 Bollinger Band Squeeze Range Contraction -2.30%

Older signals for ACOR ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Is ACOR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 29.6
52 Week Low 13.6
Average Volume 527,800
200-Day Moving Average 23.5328
50-Day Moving Average 24.344
20-Day Moving Average 23.3775
10-Day Moving Average 23.48
Average True Range 0.8815
ADX 23.76
+DI 12.49
-DI 21.57
Chandelier Exit (Long, 3 ATRs ) 22.1555
Chandelier Exit (Short, 3 ATRs ) 24.6945
Upper Bollinger Band 24.2666
Lower Bollinger Band 22.4884
Percent B (%b) 0.48
BandWidth 7.606459
MACD Line -0.2268
MACD Signal Line -0.3151
MACD Histogram 0.0883
Fundamentals Value
Market Cap 1.09 Billion
Num Shares 46.6 Million
EPS -0.94
Price-to-Earnings (P/E) Ratio -24.84
Price-to-Sales 2.27
Price-to-Book 1.76
PEG Ratio 0.51
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 24.57
Resistance 3 (R3) 24.48 23.99 24.36
Resistance 2 (R2) 23.99 23.68 24.03 24.29
Resistance 1 (R1) 23.67 23.49 23.83 23.76 24.23
Pivot Point 23.18 23.18 23.26 23.22 23.18
Support 1 (S1) 22.86 22.87 23.02 22.95 22.47
Support 2 (S2) 22.37 22.68 22.41 22.41
Support 3 (S3) 22.05 22.37 22.34
Support 4 (S4) 22.14